Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma

NCT05117814 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

CNS Lymphoma

Interventions

DRUG: Zanubrutinib

Sponsor

Peking University People's Hospital